Newborn Acquisition Corp

[1]	Excludes income attributable to ordinary shares subject to possible redemption. The Company’s net loss is adjusted for the portion of income that is attributable to ordinary share subject to possible redemption, as these shares only participate in the income of the trust account and not the losses of the Company.
[2]	The Company has not considered the effect of the warrants sold in the Initial Public Offering to purchase an aggregate of 2,875,000 shares in the calculation of diluted earnings per share subject to possible redemption, since the exercise of the warrants are contingent upon the occurrence of future events.
[3]	Excludes an aggregate of 5,114,076 ordinary shares subject to possible redemption at December 31, 2020. The Company has not considered the effect of the warrants sold in the Private Placement to purchase an aggregate of 136,250 shares in the calculation of diluted earnings per share to ordinary shares, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be antidilutive.

Statement of Cash Flows - USD ($)	9 Months Ended	12 Months Ended
Statement of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2020
Cash flow from operating activities
Net loss	$ (4,578)	$ (1,045,493)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		969,990
Change in operating assets and liabilities:
Change in prepaid expenses		(11,614)
Change in accrued payables	4,030	109,053
Net cash provided by (used in) operating activities	(548)	21,936
Cash flows from investing activities
Maturity of investment held in trust account		57,890,000
Purchase of investment held in trust account		(115,785,769)
Net cash used in investing activities		(57,895,769)
Cash flow from financing activities
Proceeds from sale of units in the public offering		57,500,000
Proceeds from sale of units in the private placement		2,445,000
Proceeds from sale of underwriter’s unit purchase option		100
Payment of costs of public offering	(195,785)	(2,044,125)
Proceeds from note payable to a related party	280,000
Proceeds from sale of ordinary shares	25,000
Net cash provided by financing activities	109,215	57,900,975
Net increase in cash	108,667	27,142
Cash at beginning of period		108,667
Cash at end of the year	$ 108,667	135,809
Supplemental disclosure of non-cash financing activities
Settlement of note payable by proceeds of private placement		$ 280,000

Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 135,809	$ 108,667
Prepaid expenses	11,614
Deferred offering costs		220,996
Total Current Assets	147,423	329,663
Cash and marketable securities held in trust account	57,895,769
Total Assets	58,043,192	329,663
Current Liabilities
Accrued payables	113,083	29,241
Note payable to a related party		280,000
Total Current Liabilities	113,083	309,241
Deferred underwriting compensation	1,437,500
Total Liabilities	1,550,583	309,241
Commitments and Contingencies
Ordinary shares subject to possible redemption; 5,114,076 (at redemption value of $10.0688 per share)	51,492,608
Shareholders’ Equity
Preferred shares, $0.0001 par value, 1,000,000 shares authorized, none issued or outstanding
Ordinary shares, $0.0001 par value, 100,000,000 shares authorized, 2,345,924 and 1,437,500 ordinary shares issued and outstanding, respectively	235	144
Additional paid- in capital	6,049,837	24,856
Accumulated deficit	(1,050,071)	(4,578)
Total Shareholders’ Equity	5,000,001	20,422
Total Liabilities and Shareholders’ Equity	$ 58,043,192	$ 329,663